Pesquisar
Karyopharm Therapeutics Inc
KPTIAdicionar à lista de desejos
9.600USD
+0.050+0.52%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
175.79MValor de mercado
PerdaP/L TTM
Mais detalhes de Karyopharm Therapeutics Inc Empresa
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Informações de Karyopharm Therapeutics Inc
Código da empresaKPTI
Nome da EmpresaKaryopharm Therapeutics Inc
Data de listagemNov 06, 2013
CEOPaulson (Richard A)
Número de funcionários279
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 06
Endereço85 Wells Avenue
CidadeNEWTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02459
Telefone16176580600
Sitehttps://karyopharm.com/
Código da empresaKPTI
Data de listagemNov 06, 2013
CEOPaulson (Richard A)
Executivos da empresa Karyopharm Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
13.01K
+4.14%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
12.50K
+3.94%
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Karyopharm Therapeutics Inc?
Os cinco principais acionistas de Karyopharm Therapeutics Inc são: Mr. Michael Mano, J.D.
Quantas instituições possuem ações da Karyopharm Therapeutics Inc (KPTI)?
Em 2026Q1, 236 instituições possuíam ações da Karyopharm Therapeutics Inc, com valor de mercado aproximado de 14.10M, representando 62.56% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 5055019.00.